A carregar...
Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies
Since approval of rituximab for treatment of B cell non-Hodgkin lymphoma, development of monoclonal antibodies (mAbs) for cancer treatment and elucidation of their cytotoxic mechanisms have been subject to intense investigations. Compelling evidence indicates that rituximab and another CD20 mAb, ofa...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The American Society for Pharmacology and Experimental Therapeutics
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4201137/ https://ncbi.nlm.nih.gov/pubmed/24944188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.114.092684 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|